Showing 4901-4910 of 5957 results for "".
- Moderna’s COVID-19 Vaccine Becomes Second to Nab EU Authorizationhttps://modernod.com/news/modernas-covid-19-vaccine-becomes-second-to-nab-eu-authorization/2478725/The European Commission on Wednesday granted a conditional marketing authorization for Moderna’s COVID‑19 vaccine mRNA-1273, making it the second coronavirus vaccine authorized in the EU. The decision comes hours after the European Medicines Agency (EMA) had recommended authorizing mRNA-127
- Birmingham Research Paves the Way for New Anti-Fibrotic Therapy for Glaucomahttps://modernod.com/news/birmingham-research-paves-the-way-for-new-anti-fibrotic-therapy-for-glaucoma/2478727/Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB, could play a key role in treating open angle glaucoma (OAG). The research, reported in
- Volk Optical Releases ClearPod to Address Mask-Related Fogging During Fundus Examinationshttps://modernod.com/news/volk-optical-releases-clearpod-to-address-mask-related-fogging-during-fundus-examinations/2478724/Volk Optical announced the release their newest product, the ClearPod, which aims to solve the problem of mask-related fogging during fundus examinations. This patent-pending design has been created in collaboration with ophthalmologists Bradley Sacher, MD, a cataract specialist, and Jerem
- Study: Hospitals At or Near Full COVID-19 ICU Capacity Increase by 90% Over Past Few Monthshttps://modernod.com/news/study-hospitals-at-or-near-full-covid-19-icu-capacity-increase-by-90-over-past-few-months/2478722/A new study found a 90% increase in hospitals reaching intensive care unit (ICU) capacity from July through December, with rural hospitals facing the biggest capacity issues, according to a FierceHealthcare
- Norlase Receives CE Mark Approval for LION Green Laser Systemhttps://modernod.com/news/norlase-receives-ce-mark-approval-for-lion-green-laser-system/2478718/Norlase announced that it has been granted the European CE Mark for the LION green laser system. LION combines the Keeler Vantage Plus diagnostic indirect with Norlase’s compact laser technology into one device. With LION’s untethered and portable design, physicians can move freely between treatm
- Samsara Vision Appoints Three New Members to the Board of Directorshttps://modernod.com/news/samsara-vision-appoints-three-new-members-to-the-board-of-directors/2478712/Samsara Vision, a developer of visual prosthetic devices for patients living with late-stage age-related macular degeneration (AMD), has announced the appointment of three new members to its Board of Directors: Jonathan H. Talamo, MD; Tracy M. Valorie; and David Schiff, joining Thierry Clidiere,
- Fewer New Cases of Intraocular Inflammation After First Year of Abicipar in AMD Patientshttps://modernod.com/news/fewer-new-cases-of-intraocular-inflammation-after-first-year-of-abicipar-in-amd-patients/2478703/Most cases of intraocular inflammation in patients with neovascular age-related macular degeneration (nAMD) who take AbbVie’s investigational drug abicipar pegol develop during the first year of treatment, according to a new report of two-year efficacy and safety results from a couple of pi
- Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombihttps://modernod.com/news/eyenovia-submits-nda-to-fda-for-pharmacologic-mydriasis-with-mydcombi/2478701/Eyenovia announced that it has submitted a new drug application (NDA) to the FDA for MydCombi, a fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision smart delivery system. The NDA submission follow
- Timing of Cataract Removal in Infancy May Affect Glaucoma Riskhttps://modernod.com/news/timing-of-cataract-removal-in-infancy-may-affect-glaucoma-risk/2478700/A decade after undergoing cataract removal in infancy a substantial and increasing proportion of patients develop glaucoma or become glaucoma suspects, according to a secondary analysis of a randomized clinical trial, Reuters reported.
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d